Methods and compositions for oral administration of insulin
a technology of compositions and oral administration, applied in the direction of antibody medical ingredients, inorganic non-active ingredients, metabolic disorders, etc., can solve the problems of poor patient acceptability, compliance, difficulty in matching, etc., and achieve the effect of lowering blood glucose levels
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
Problems solved by technology
Method used
Image
Examples
example 1
Preparation of Insulin Composition
[0160]An insulin composition (Formulation I) was produced, using the following ingredients:
[0161]Insulin Actrapid™, 9 ml
[0162]Olive oil, 11 ml
[0163]Benefiber™, 7 g
[0164]Silica R972, 1.2 g
[0165]Oblepicha, 9 ml
[0166]Sesame Oil up to 75 ml
Insulin was combined with sea buckthorn (oblepicha) oil and stirred at 20 rpm for 2 min, and then at 50 rpm for 5 min. Benefiber™ (Novartis Nutrition GmbH, Germany) and hydrophobic silica R972 were placed into a beaker and mixed by vortexing at 900 rpm for 5 min. Association between the Benefiber™ and the silica was determined by the mixture's ability to float after being placed on the surface of a water-filled beaker. The Benefiber™ / silica mixture was added to the oil-insulin solution and stirred for 25 minutes at 50 rpm. Olive oil was added, and the mixture was stirred at 50 rpm for 3 min. The volume was brought up to 75 ml with sesame oil, and the mixture was stirred at 50 rpm for 20 min. The product was stored ref...
example 2
Additional Actrapid™ Matrix Carrier Composition Formulated for Short-Life
[0167]An additional Actrapid™ formulation (Formulation II) using the following ingredients was designed for short-term insulin release:
[0168]Insulin Actrapid™, 1 ml
[0169]Olive oil, 1.5 ml.
[0170]Ambrotose™, 0.7 g.
[0171]Silica R972, 0.1 g
[0172]Oblepicha oil, 1.5 ml
[0173]Evening primrose oil, 5 ml
[0174]0.7 g of rice polysaccharides (Ambrotose™, Mannatech Inc, Coppell, Tex. 75019, USA) was combined with 0.1 g hydrophobic fumed silica R972 (Degussa Inc), and mixed by vortexing at 900 rpm for 5 min. Association between the Ambrotose™ and the silica was determined by the mixture's ability to float after being placed on the surface of a water-filled beaker 1 ml Actrapid™ insulin were added and stirred for 15 minutes at 50 rpm. 1.5 ml of olive oil was added and stirred for 2 minutes at 100 rpm with a magnetic stirrer. Sea buckthorn (oblepicha) oil was added and stirred for 2 minutes at 100 rpm with a magnetic stirrer. T...
example 3
Longterm Release Actrapid™ Matrix Carrier Composition
[0177]The following formulation (Formulation III) was manufactured to provide longer-term Actrapid™ release:
[0178]Olive oil, 10 ml.
[0179]Benefiber™, 1.5 g.
[0180]Insulin Actrapid™, 2 ml
[0181]Silica R972, 0.7 g
[0182]Oblepicha oil, 10 ml
[0183]Evening primrose oil, 5 ml
[0184]Linseed oil, up to 40 ml.
[0185]Benefiber™ was combined with hydrophobic fumed silica R972 and mixed by vortexing at 900 rpm for 5 minutes. Association between the Benefiber™ and the silica was determined by the mixture's ability to float after being placed on the surface of a water-filled beaker. Actrapid™ insulin was added and stirred for 15 minutes at 50 rpm. Evening primrose oil was added and stirred for 2 minutes at 100 rpm with a magnetic stirrer. Sea buckthorn (oblepicha) oil was added and stirred for 2 minutes at 100 rpm with a magnetic stirrer. Olive oil was added and stirred for 2 minutes at 100 rpm with a magnetic stirrer. The volume was brought up to 40...
PUM
| Property | Measurement | Unit |
|---|---|---|
| size | aaaaa | aaaaa |
| size | aaaaa | aaaaa |
| particle size | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More